Calpain-mediated down-regulation of myelin-associated glycoprotein in lysophosphatidic acid-induced neuropathic pain

J Neurochem. 2010 May;113(4):1002-11. doi: 10.1111/j.1471-4159.2010.06664.x.

Abstract

Lysophosphatidic acid receptor (LPA(1)) signaling initiates neuropathic pain through demyelination of the dorsal root (DR). Although LPA is found to cause down-regulation of myelin proteins underlying demyelination, the detailed mechanism remains to be determined. In the present study, we found that a single intrathecal injection of LPA evoked a dose- and time-dependent down-regulation of myelin-associated glycoprotein (MAG) in the DR through LPA(1) receptor. A similar event was also observed in ex vivo DR cultures. Interestingly, LPA-induced down-regulation of MAG was significantly inhibited by calpain inhibitors (calpain inhibitor X, E-64 and E-64d) and LPA markedly induced calpain activation in the DR. The pre-treatment with calpain inhibitors attenuated LPA-induced neuropathic pain behaviors such as hyperalgesia and allodynia. Moreover, we found that sciatic nerve injury activates calpain activity in the DR in a LPA(1) receptor-dependent manner. The E-64d treatments significantly blocked nerve injury-induced MAG down-regulation and neuropathic pain. However, there was no significant calpain activation in the DR by complete Freund's adjuvant treatment, and E-64d failed to show anti-hyperalgesic effects in this inflammation model. The present study provides strong evidence that LPA-induced calpain activation plays a crucial role in the manifestation of neuropathic pain through MAG down-regulation in the DR.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Calpain / metabolism*
  • Cysteine Proteinase Inhibitors / pharmacology
  • Demyelinating Diseases / etiology
  • Demyelinating Diseases / metabolism*
  • Demyelinating Diseases / physiopathology
  • Disease Models, Animal
  • Enzyme Activation / drug effects
  • Enzyme Activation / physiology
  • Leucine / analogs & derivatives
  • Leucine / pharmacology
  • Lysophospholipids / toxicity
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Myelin-Associated Glycoprotein / metabolism*
  • Neurotoxins / toxicity
  • Peripheral Nervous System Diseases / metabolism*
  • Peripheral Nervous System Diseases / physiopathology
  • Receptors, Lysophosphatidic Acid / drug effects
  • Receptors, Lysophosphatidic Acid / metabolism
  • Sciatic Neuropathy / metabolism
  • Sciatic Neuropathy / physiopathology
  • Sensory Receptor Cells / metabolism*
  • Sensory Receptor Cells / pathology
  • Spinal Nerve Roots / metabolism*
  • Spinal Nerve Roots / pathology

Substances

  • Cysteine Proteinase Inhibitors
  • Lysophospholipids
  • Myelin-Associated Glycoprotein
  • Neurotoxins
  • Receptors, Lysophosphatidic Acid
  • Calpain
  • Leucine
  • lysophosphatidic acid
  • E 64